secwatch.observer — SEC 8-K summary
======================================

Issuer:     X4 Pharmaceuticals, Inc (XFOR)
CIK:        0001501697
Form:       8-K
Filed at:   2023-06-15T23:59:59+00:00
Accession:  0001628280-23-022266
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

X4 Pharmaceuticals stockholders elect three directors and approve all proposals at 2023 annual meeting
--------------------------------------------------------------------------------

- Elected Gary J. Bridger, Francoise de Craecker, and Murray W. Stewart as directors for three-year terms.
- Ratified PricewaterhouseCoopers LLP as independent auditor for FY2023 with 94.3M votes for.
- Advisory vote on named executive officer compensation approved with 59.3M for vs 8.0M against.
- Stockholders preferred a one-year frequency for future say-on-pay votes; board adopted annual votes.
- Approved Amended and Restated 2017 Employee Stock Purchase Plan with 66.7M votes for.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501697/000162828023022266/0001628280-23-022266-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501697/000162828023022266/xfor-20230613.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-022266

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer